Using the latest genomic research to inform personalised cancer care
The MPCCC Precision Oncology Program coordinates research and clinical care for patients with rare, advanced stage and therapy-resistant cancers.
The program supports analyses of comprehensive genome profiling data, enabling health professionals to understand the genetic variations of a patient’s cancer and to recommend the best treatment options available.
MPCCC’s Molecular Tumour Boards provide collaborative forums for cancer health professionals and researchers to discuss and interpret the results of genome profiling. These meetings help to guide decision making about treatments for individual patients. Current MPCCC Molecular Tumour Boards specialise in:
- pancreatic and upper gastrointestinal cancers
- rare cancers and cancers of unknown primary site
- prostate cancer
- thyroid cancer.
In addition, the MPCCC Precision Oncology Program provides educational opportunities to prepare the cancer workforce to apply precision oncology in ways that support excellence in patient care.
Local, interstate and international guest speakers are invited to present at Precision Oncology Seminars held across MPCCC partner health services on topics such as:
- genetic sequencing of solid tumours
- novel therapies for high-risk childhood cancers
- cancer biomarker research and discovery in immunotherapy
- the Australian Genomic Cancer Medicine Program – a national precision oncology initiative
- cancers of unknown primary
- health economics of comprehensive genome profiling compared with ‘standard of care’ genetic testing
- clinical bioinformatics
- circulating tumour DNA (‘liquid biopsies’) for molecular disease monitoring.
The MPCCC Precision Oncology Program has been made possible by funding from the Victorian Government and Monash University.
‘The MPCCC Precision Oncology Program provides a fantastic opportunity for clinicians and researchers to become involved in applying cutting-edge standards of care in ways that improve the quality of care of our patients.’
Professor Mark Shackleton
Clinical Lead, MPCCC Precision Oncology Program; Director of Oncology, Alfred Health; Professor of Oncology, Monash University
‘This program will help make tumour profiling widely accessible through MPCCC partner health services.’
Dr Muhammad Alamgeer
Medical Oncologist, Monash Health
‘An important role of the MPCCC is to enable our academic and clinical workforce to collaborate across organisational boundaries, to connect and share information and to prepare for the future needs of our community. The MPCCC Precision Oncology Program provides a platform to achieve this.’
Professor Melissa Southey
Research Director, MPCCC; Chair of Precision Medicine, Monash University
‘I want to thank MPCCC’s health and research partners for their hard work and commitment to improving the health and wellbeing of the people of Victoria.’
Mr Anthony Carbines
Parliamentary Secretary for Health, Victorian Government